295 related articles for article (PubMed ID: 26559690)
1. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
So W; Crandon JL; Hamada Y; Nicolau DP
J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
[TBL] [Abstract][Full Text] [Related]
2. Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.
Ghazi IM; Grupper M; Nicolau DP
Infect Dis (Lond); 2017; 49(11-12):831-839. PubMed ID: 28758820
[TBL] [Abstract][Full Text] [Related]
3. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
[TBL] [Abstract][Full Text] [Related]
4. Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system.
Ghazi IM; Grupper M; Nicolau DP
Ann Clin Microbiol Antimicrob; 2017 Jan; 16(1):2. PubMed ID: 28095918
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.
Bowker KE; Noel AR; Tomaselli S; Attwood M; MacGowan AP
J Antimicrob Chemother; 2018 May; 73(5):1305-1313. PubMed ID: 29562340
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
[TBL] [Abstract][Full Text] [Related]
7. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
Sutherland CA; Verastegui JE; Nicolau DP
Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):39. PubMed ID: 27316973
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Noel AR; Bowker KE; Attwood M; MacGowan AP
J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach.
Vourli S; Tsala M; Kotsakis S; Daikos GL; Tzouvelekis L; Miriagou V; Zerva L; Meletiadis J
J Pharm Sci; 2016 Apr; 105(4):1513-8. PubMed ID: 27019965
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications.
Tsala M; Vourli S; Kotsakis S; Daikos GL; Tzouvelekis L; Zerva L; Miriagou V; Meletiadis J
J Med Microbiol; 2016 Mar; 65(3):211-218. PubMed ID: 26697851
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
[TBL] [Abstract][Full Text] [Related]
13. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.
Sharma R; Patel S; Abboud C; Diep J; Ly NS; Pogue JM; Kaye KS; Li J; Rao GG
Int J Antimicrob Agents; 2017 Feb; 49(2):224-232. PubMed ID: 28040408
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
[TBL] [Abstract][Full Text] [Related]
15. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.
Lim TP; Cai Y; Hong Y; Chan EC; Suranthran S; Teo JQ; Lee WH; Tan TY; Hsu LY; Koh TH; Tan TT; Kwa AL
Antimicrob Agents Chemother; 2015 May; 59(5):2515-24. PubMed ID: 25691628
[TBL] [Abstract][Full Text] [Related]
16. [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
Elkhaïli H; Pompei D; Peter JD; Linger L; Salmon J; Levêque D; Niedergang S; Salmon Y; Thierry RC; Monteil H; Jehl F
Pathol Biol (Paris); 1997 May; 45(5):347-56. PubMed ID: 9296083
[TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
Wiskirchen DE; Koomanachai P; Nicasio AM; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2011 Apr; 55(4):1420-7. PubMed ID: 21282442
[TBL] [Abstract][Full Text] [Related]
18. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B.
Lim TP; Lee W; Tan TY; Sasikala S; Teo J; Hsu LY; Tan TT; Syahidah N; Kwa AL
PLoS One; 2011; 6(12):e28177. PubMed ID: 22162759
[TBL] [Abstract][Full Text] [Related]
19. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
Louie A; Liu W; Fikes S; Brown D; Drusano GL
Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.
Noel AR; Attwood M; Bowker KE; Kim A; Krause KM; MacGowan AP
Int J Antimicrob Agents; 2019 Nov; 54(5):626-632. PubMed ID: 31299297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]